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Background-—SPRINT (Systolic Blood Pressure Intervention Trial) and the ACCORD (Action to Control Cardiovascular Risk in
Diabetes) blood pressure trial used similar interventions but produced discordant results. We investigated whether differences in
systolic blood pressure (SBP) response contributed to the discordant trial results.
Methods and Results-—We evaluated the distributions of SBP response during the first year for the intensive and standard
treatment groups of SPRINT and ACCORD using growth mixture models. We assessed whether significant differences existed
between trials in the distributions of SBP achieved at 1 year and the treatment-independent relationships of achieved SBP with
risks of primary outcomes defined in each trial, heart failure, stroke, and all-cause death. We examined whether visit-to-visit
variability was associated with heterogeneous treatment effects. Among the included 9027 SPRINT and 4575 ACCORD
participants, the difference in mean SBP achieved between treatment groups was 15.7 mm Hg in SPRINT and 14.2 mm Hg in
ACCORD, but SPRINT had significantly less between-group overlap in the achieved SBP (standard deviations of intensive and
standard groups, respectively: 6.7 and 5.9 mm Hg in SPRINT versus 8.8 and 8.2 mm Hg in ACCORD; P<0.001). The relationship
between achieved SBP and outcomes was consistent across trials except for stroke and all-cause death. Higher visit-to-visit
variability was more common in SPRINT but without treatment-effect heterogeneity.
Conclusions-—SPRINT and ACCORD had different degrees of separation in achieved SBP between treatment groups, even as they
had similar mean differences. The greater between-group overlap of achieved SBP may have contributed to the discordant trial
results. ( J Am Heart Assoc. 2017;6:e007509. DOI: 10.1161/JAHA.117.007509.)
Key Words: ACCORD (Action to Control Cardiovascular Risk in Diabetes) • outcome • systolic blood pressure • SPRINT (Systolic
Blood Pressure Intervention Trial)
C linicians and patients face uncertainty about theoptimal systolic blood pressure (SBP) goals to reduce
adverse cardiovascular outcomes.1 In recent years, 2 major
studies, SPRINT (Systolic Blood Pressure Intervention Trial)2
and the ACCORD (Action to Control Cardiovascular Risk in
Diabetes) blood pressure trial,3 tested the cardiovascular
benefit of intensive (<120 mm Hg) versus standard
(<140 mm Hg) SBP control. Although both trials used
similar interventions and achieved similar average SBP, they
had different results. SPRINT, which enrolled people without
diabetes mellitus, found a benefit with an intensive SBP
target, but ACCORD, which enrolled people with diabetes
mellitus, did not. Several theories have attributed the
discordant results to differences in outcome definitions,
sample sizes, trial participant characteristics, or blood
pressure measurement technique.1,4,5
From the Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (C.H., A.C.C., F.W., S.-X.L., H.M.K); National Clinician Scholars
Program (S.S.D.) and Section of Cardiovascular Medicine (A.C.C., F.W., H.M.K.), Department of Internal Medicine, Yale School of Medicine, New Haven, CT;
Departments of Biostatistics (H.L.) and Health Policy and Management (H.M.K.), Yale School of Public Health, New Haven, CT; Veterans Affairs Connecticut Healthcare
System, West Haven, CT (S.S.D.); Center for Healthcare Advancement and Outcomes Research and Miami Cardiac and Vascular Institute, Baptist Health South Florida,
Miami, FL (K.N.).
Accompanying Tables S1 through S5 and Figures S1 through S3 are available at http://jaha.ahajournals.org/content/6/11/e007509/DC1/embed/inline-supple
mentary-material-1.pdf
Correspondence to: Harlan M. Krumholz, MD, SM, 1 Church Street, Suite 200, New Haven, CT 06510. E-mail: harlan.krumholz@yale.edu
Received August 28, 2017; accepted October 24, 2017.
ª 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-
commercial and no modifications or adaptations are made.
DOI: 10.1161/JAHA.117.007509 Journal of the American Heart Association 1
ORIGINAL RESEARCH








In this study, we explore an alternative theory: The
different outcome results in SPRINT and ACCORD were
caused by differences in the SBP responses of the partici-
pants. Previous research has demonstrated marked variations
of SBP response among participants within a treatment
group.6 Although average SBPs appeared similar between
SPRINT and ACCORD, we sought to understand whether there
were unappreciated variations in SBP response. To address
the proposed theory, we tested 3 hypotheses. First, we
determined whether there were differences between trials in
the distributions of achieved SBP, especially in the separation
of their respective treatment groups. Second, we investigated
whether the achieved SBP had different relationships with
cardiovascular outcomes between trials, independent of
treatment strategy. Third, we sought to determine whether
there were differences between trials in the distribution of
visit-to-visit variability, also known to be prognostic,7,8 and
whether visit-to-visit variability was associated with treat-
ment-effect heterogeneity.
Methods
Data Source and Study Design
Data are available, on request, from the National Institutes of
Health. The SPRINT and ACCORD trials have been described
previously.2,3,9,10 Briefly, SPRINT was a randomized
multicenter trial to determine whether an intensive control
strategy (SBP <120 mm Hg) was superior to a standard
strategy (SBP <140 mm Hg) among 9361 nondiabetic par-
ticipants aged ≥50 years at increased cardiovascular risk. The
ACCORD blood pressure trial tested the intensive versus
standard SBP control strategies among 4733 participants with
diabetes mellitus at high cardiovascular risk. The median
follow-up durations of SPRINT and ACCORD were 3.26 and
4.7 years, respectively.
We used the SBP measurements during each trial’s first
year after randomization to assess the SBP responses to
intensive or standard treatment (Figure 1A). We studied 5
outcomes: the primary outcome defined in SPRINT, the
primary outcome defined in ACCORD, heart failure, stroke,
and all-cause death. Participants were followed from 1 year
until the first occurrence of an outcome event or the end of
Figure 1. Flowchart of study participants for analysis. A, Data
points for systolic blood pressure (SBP) response assessment and
the association of SBP response and cardiovascular outcomes. B,
Exclusion criteria applied to obtain the study sample. ACCORD
indicates Action to Control Cardiovascular Risk in Diabetes;
SPRINT, Systolic Blood Pressure Intervention Trial.
Clinical Perspective
What Is New?
• Our study shows a difference in the distributions of systolic
blood pressure (SBP) achieved in SPRINT (Systolic Blood
Pressure Intervention Trial) and ACCORD (Action to Control
Cardiovascular Risk in Diabetes): ACCORD had less sepa-
ration of the SBP between intensive and standard treatment
groups compared with SPRINT, even though they achieved
similar average SBP levels.
• Meanwhile, the relationship of SBP with cardiovascular
outcomes was largely similar in both trials.
• These results are consistent with a theory that the less
between-group separation in ACCORD may help explain
discrepancy between the results in SPRINT and ACCORD.
What Are the Clinical Implications?
• ACCORD may have demonstrated a smaller cardiovascular
benefit than SPRINT because ACCORD had poorer separa-
tion between treatment groups compared with SPRINT.
• Given this finding, ACCORD may be seen as consistent with
SPRINT’s finding that an SBP goal of 120 mm Hg is
associated with cardiovascular benefit compared with
140 mm Hg.
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follow-up for each trial. We excluded participants who had
outcome events during the first year (n=221 for SPRINT and
n=117 for ACCORD) and those with no follow-up SBP (n=113
for SPRINT and n=41 for ACCORD; Figure 1B). All participants
provided written informed consent for participation in SPRINT
and ACCORD. Our analysis was approved by the institutional
review board at Yale University.
SBP Measurements and Evaluation of SBP
Response Distributions
To evaluate the SBP response distributions, we used the SBP
measurements from all visits during the first year of each trial.
We used 1 year of data to allow adequate time for partici-
pants assigned to either intensive or standard strategies to
reach their SBP goals and to increase the precision of the
estimation of visit-to-visit variability. A total of 7 visits
(baseline and 1, 2, 3, 6, 9, and 12 months) for both treatment
groups in SPRINT and 9 visits (baseline and 1, 2, 3, 4, 6, 8, 10,
and 12 months) for the intensive group and 5 visits (baseline
and 1, 4, 8, and 12 months) for the standard group in
ACCORD were included.
We used growth mixture modeling11 to estimate the
distribution of achieved SBP and visit-to-visit variability for
each treatment group of each trial. Because of the larger
initial drop of SBP in the intensive group, a conventional visit-
to-visit variability metric based on standard deviations tends
to produce higher variability for intensive-group participants
than for participants in the standard group and thus is not
applicable. Growth mixture modeling can account for the SBP
trends and estimate the intraindividual variance across visits
(visit-to-visit variability) based on the fluctuations around the
SBP trends. In addition, growth mixture modeling captures the
interindividual variance of SBP, facilitating estimation for the
distribution of achieved SBP. More specifically, we derived 4
growth mixture models, each for participants from the same
treatment group of the same trial. For each model, we used a
piecewise linear function of time to model the SBP trend,
mixture components to model distinct classes (strata) of visit-
to-visit variability, and mixed effects to model the interindi-
vidual variance of achieved SBP. Finally, to compare trials in
the distribution of visit-to-visit variability, we restricted the
mixture components to be the same across 4 models. The
number of visit-to-visit variability classes was determined
based on Bayesian information criteria and the restriction that
the percentage of participants in each class should not be
<5%. Participants were assigned to the visit-to-visit variability
class corresponding to their highest posterior probability.
Furthermore, we calculated the estimated achieved SBP at
1 year for all participants from the models using the empirical
Bayes method,12 including those with missing SBP measure-
ment at 1 year.
Clinical Outcomes
Clinical outcomes included the primary outcome of SPRINT,
the primary outcome of ACCORD, heart failure, stroke, and all-
cause death, as defined in their respective trials.2,3 A
combination of secondary outcomes from ACCORD was used
to construct a composite outcome comparable to SPRINT’s
primary outcome: nonfatal myocardial infarction, nonfatal
stroke, congestive heart failure, and death from cardiovascu-
lar causes. A combination of secondary outcomes from
SPRINT was used to construct a composite outcome compa-
rable to ACCORD’s primary outcome: myocardial infarction,
stroke, and death from cardiovascular causes. We included
outcomes occurring from 1 year after randomization through
the end of follow-up for each trial.
Statistical Analyses
We first evaluated the distributions of achieved SBP and visit-
to-visit variability for the intensive and standard treatment
groups in SPRINT and ACCORD by modeling the SBP
responses during the first year via growth mixture modeling.
We used likelihood ratio tests to assess whether there were
significant differences in the mean and variance of achieved
SBP at 1 year between SPRINT and ACCORD in their
respective treatment groups. The degree of separation
between treatment groups in the distribution of achieved
SBP was also assessed by the overlap coefficient,13 which
quantifies the overlap area between 2 probability density
functions.
We next used the achieved SBP of individual participants at
1 year estimated from the growth mixture models to examine
the association of achieved SBP with outcomes. Each
participant was also assigned to a visit-to-visit variability
class according to the estimated growth mixture models.
First, for all participants of each trial, regardless of treatment
assignment, we assessed differences in characteristics at
baseline and during the first year after randomization across
tertiles of achieved SBP, using t tests or Wilcoxon–Mann–
Whitney tests for continuous variables and v2 tests for
categorical variables. The tertiles were determined using the
pooled participants from both trials. Next, Cox proportional
hazards regression models were used to calculate outcome
risks associated with increasing tertiles of achieved SBP
(modeling tertile as an ordinal variable) without and with
adjustment for baseline demographics and blood pressure,
past medical history, visit adherence, and visit-to-visit
variability. Differences in trends between trials were assessed
by comparing Cox hazard models derived from pooled
participants of both trials with models derived separately
from participants of SPRINT or ACCORD using Wald tests. To
account for different baseline risks of the 2 trial populations,
stratified Cox hazard models were used for the pooled
DOI: 10.1161/JAHA.117.007509 Journal of the American Heart Association 3























participants. In addition, we tested the interaction of treat-
ment with achieved SBP modeled as a continuous variable for
the middle tertile, which contained considerable percentages
of participants from both treatment groups. Furthermore, we
assessed adjusted hazard ratios of outcomes associated with
the achieved SBP, modeled as a continuous variable, using
restricted cubic splines. The proportionality assumption of the
Cox hazard model was tested by examining the Schoenfeld
residuals.14
Finally, we determined whether there were significant
differences in the distributions of visit-to-visit variability
between SPRINT and ACCORD by comparing percentages of
participants in the classes of visit-to-visit variability identified
from the growth mixture models using v2 tests. To evaluate
the impact of the visit-to-visit variability on treatment effect in
outcomes, we calculated the adjusted hazard ratios for
outcomes associated with intensive compared with standard
treatment using Cox proportional hazards regression models.
We also tested the interaction of treatment with visit-to-visit
variability class.
Missing baseline characteristics were imputed with 10
data sets using chained equations via multiple imputation.15
For sensitivity analyses, we repeated the evaluation of SBP
response distributions and calculation of Cox proportional
hazard ratios for participants without missing follow-up SBP
measurements during the first year. Growth mixture
modeling was performed using R package OpenMx (version
2.5.2).16 Multiple imputation was performed using R
package mice (version 2.25),17 and a continuous hazard
ratio was calculated using R package rms (version 5.1-1).18
All P values reported are nominal, and P<0.1 was




Of the 9361 SPRINT participants and 4733 ACCORD blood
pressure trial participants, 9027 (96.4%) from SPRINT and
4575 (96.7%) from ACCORD were included in our analyses
(Figure 1B). When modeling the SBP responses for these
participants using growth mixture models, based on Bayesian
information criteria and the percentage of participants in each
class, the 3-class visit-to-visit variability models best fit the
data (Table S1).
Figure 2 shows, for SPRINT (Figure 2A) and ACCORD
(Figure 2B), the estimated mean SBP trends (solid lines) and
individual SBP measurements over time (gray circle markers)
associated with each visit-to-visit variability class in the
intensive (top row) and standard treatment groups (bottom
row). Three classes of visit-to-visit variability with increasing
Figure 2. Results of modeling systolic blood pressure (SBP) response in (A) SPRINT (Systolic Blood Pressure Intervention Trial) and (B)
ACCORD (Action to Control Cardiovascular Risk in Diabetes), by visit-to-visit variability classes. Solid lines represent the estimated mean SBP
trends. gray circle markers represent individual SBP measurements over time. Red dashed lines are reference lines of 120 and 140 mm Hg.
Classes 1, 2, and 3 have increasing values of visit-to-visit variability of 5.7, 10.8, and 17.9 mm Hg, respectively.
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values were identified (referred to as classes 1, 2, and 3), with
estimated values of 5.7, 10.8, and 17.9 mm Hg.
Distributions of Achieved SBP in SPRINT and
ACCORD
The distributions of achieved SBP at 1 year in the intensive
and standard treatment groups were significantly different
between SPRINT and ACCORD (Figure 3). First, SPRINT and
ACCORD had small but statistically significant differences in
the mean achieved SBP at 1 year in the 2 treatment groups
(120.2 and 135.9 mm Hg in SPRINT versus 120.0 and
134.2 mm Hg in ACCORD; P<0.001), resulting in a slightly
smaller between-group mean difference in ACCORD
(14.2 mm Hg) than in SPRINT (15.7 mm Hg). Second,
ACCORD had larger standard deviations of achieved SBPs at
1 year in the intensive and standard groups (8.8 and
8.2 mm Hg, respectively, in ACCORD versus 6.7 and
5.9 mm Hg, respectively, in SPRINT; P<0.001). The overlap
area between intensive and standard groups in the distribu-
tion of achieved SBP is 20.2% for SPRINT and 40.3% for
ACCORD.
Characteristics of participants by tertile of their estimated
achieved SBP at 1 year are presented in Table 1. ACCORD
had more participants from the intensive group in the highest
tertile of achieved SBP compared with SPRINT (8.1% versus
1.2%). For both trials, participants with higher achieved SBP
were older, had worse kidney function, and had higher
Framingham Risk Scores, urine albumin/creatinine ratios, and
baseline blood pressure.
Association of Achieved SBP With Outcomes in
SPRINT and ACCORD
We found no significant differences between SPRINT and
ACCORD in the relationship of tertiles of estimated SBP
achieved at 1 year and each outcome in unadjusted or adjusted
models, except for stroke and all-cause death (Table 2).
Incidence of the primary outcome of SPRINT, the primary
outcome of ACCORD, and heart failure were all progressively
higher at higher tertiles of achieved SBP; furthermore, incidence
of stroke was higher at higher achieved SBP in ACCORD but not
in SPRINT, whereas incidence of all-cause death was higher at
higher achieved SBP in SPRINT but not in ACCORD. After
multivariable adjustment, the hazard ratio comparing the
pooled participants from both trials in the highest versus
lowest tertile of achieved SBP was 1.50 (95% confidence
interval, 1.24–1.81) for the primary outcome of SPRINT, 1.35
(95% confidence interval, 1.09–1.68) for the primary outcome
of ACCORD, and 1.97 (95% confidence interval, 1.39–2.80) for
heart failure. No violation of the proportionality assumption was
found in the Cox hazardmodels. In addition, for all outcomes, no
interaction of treatment with achieved SBP was found for
participants in the middle tertile.
The estimated achieved SBP at 1 year modeled as a
continuous variable showed a linear relationship with risks of
Figure 3. Distribution of achieved systolic blood pressure (SBP) at 1 year in intensive and standard treatment groups of (A) SPRINT (Systolic
Blood Pressure Intervention Trial) and (B) ACCORD (Action to Control Cardiovascular Risk in Diabetes) estimated from modeling the SBP
response during the first year. Error bars represent 1 SD from the mean SBP.
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the primary outcomes of SPRINT and ACCORD and heart failure
(Figure S1). For stroke, a gradual increase in risk for higher
achieved SBP was found in ACCORD but not in SPRINT. For all-
cause death, risk in SPRINT increased progressively with
achieved SBP until130 mm Hg, whereas the risk in ACCORD
did not change much over the range of achieved SBP.
Distribution of Visit-to-Visit Variability and
Association With Treatment Effect Heterogeneity
SPRINT and ACCORD also had significant differences in
percentages of participants from intensive and standard
treatment groups in the 3 classes of visit-to-visit variability
Table 1. Participant Characteristics by Estimated SBP Achieved at 1 Year
Characteristic
SPRINT ACCORD




















Intensive group, n (%) 2963 (99.9) 1526 (53.4) 37 (1.2) <0.001 1504 (95.9) 675 (40.2) 108 (8.1) <0.001
Baseline characteristics
Age, y 66.99.1 68.49.4 68.19.5 <0.001 62.06.6 62.86.5 63.36.8 <0.001
White, n (%) 1698 (57.2) 1704 (60.0) 1815 (56.6) 0.859 995 (63.5) 1006 (60.0) 683 (51.4) <0.001
Female, n (%) 1052 (35.5) 1000 (35.0) 1160 (36.2) 0.541 756 (48.2) 796 (47.4) 627 (47.2) 0.572
Body mass index, kg/m2 30.35.8 29.75.9 29.65.5 <0.001 32.25.6 32.35.4 31.95.4 0.082
Framingham Risk Score, % 22.911.8 25.012.4 26.012.8 <0.001 32.216.1 34.916.9 38.416.6 <0.001
Estimated GFR, mL/min/
1.73 m2
73.020.3 71.320.9 71.320.4 0.002 91.722.8 90.522.9 89.823.7 0.029
Cholesterol, mg/dL
Total 188.841.6 190.141.5 191.640.3 0.007 192.242.3 191.041.6 192.042.0 0.855
High-density lipoprotein 52.013.5 53.615.1 53.114.8 0.002 46.212.9 45.613.0 46.712.9 0.425
Triglycerides, mg/dL 126.184.5 124.184.3 127.1100.3 0.630 185.4131.0 188.8131.2 176.0122.1 0.065
Glucose, mg/dL 99.213.7 98.414.0 98.813.0 0.268 173.453.8 175.654.8 171.855.6 0.473
Ratio of urinary albumin
(mg) to creatinine (g)
33.7164.5 43.7161.6 44.4170.3 0.012 54.0181.2 74.7219.8 127.3330.6 <0.001
Aspirin use, n (%) 1539 (51.9) 1469 (51.4) 1590 (49.6) 0.074 844 (53.8) 906 (54.0) 649 (48.8) 0.009
Statin use, n (%) 1281 (43.2) 1255 (43.9) 1385 (43.2) 0.925 1044 (66.6) 1095 (65.3) 845 (63.6) 0.097
Antihypertensive medication
use, n (%)
2690 (90.7) 2584 (90.5) 2897 (90.4) 0.685 1358 (86.6) 1454 (86.7) 1201 (90.4) 0.003
Smoking, n (%) 418 (14.1) 367 (12.9) 400 (12.5) 0.063 190 (12.1) 191 (11.4) 147 (11.1) 0.369
Cardiovascular disease,
n (%)
602 (20.3) 584 (20.4) 594 (18.5) 0.078 538 (34.3) 533 (31.8) 436 (32.8) 0.357
Blood pressure, mm Hg
Systolic 135.814.1 139.716.3 143.215.4 <0.001 134.014.3 137.914.8 146.014.1 0.001
Diastolic 77.911.1 77.512.2 79.112.2 <0.001 74.69.8 75.69.9 77.59.8 <0.001
Characteristics 0–1 year after randomization
No. antihypertensive
medications
2.50.9 2.21.1 2.00.9 <0.001 2.61.0 2.51.2 2.61.1 0.138
No. changes in no.
antihypertensive medications
0.91.0 1.41.2 1.11.1 <0.001 1.71.3 1.71.4 1.51.3 0.007
Visit adherence, n (%)* 2575 (86.8) 2314 (81.0) 2692 (84.0) 0.004 1116 (71.2) 1304 (77.7) 1141 (85.9) <0.001
Values are meanSD except as noted. ACCORD indicates Action to Control Cardiovascular Risk in Diabetes; GFR, glomerular filtration rate; SBP, systolic blood pressure; SPRINT, Systolic
Blood Pressure Intervention Trial.
*Visit adherence was defined as not missing any visit during the first year after randomization. SPRINT required the intensive and standard groups to have visits at 1, 3, 6, 9, and 12 mo.
ACCORD required the intensive group to have visits at 1, 2, 3, 4, 6, 8, 10, and 12 mo and the standard group to have visits at 1, 4, 8, and 12 mo.
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Table 2. Post–1-Year Outcomes Associated With Estimated SBP Achieved at 1 Year
Variable Participants
Tertile of Achieved SBP
P Value for Trend
P Value for Trial
Heterogeneity of HRs<122 mm Hg 122–134 mm Hg >134 mm Hg
SPRINT primary outcome (myocardial infarction, acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes)
No. events (%) SPRINT 98 (3.3) 126 (4.4) 156 (4.9) 0.002
ACCORD 115 (7.3) 172 (10.3) 154 (11.6) <0.001
Unadjusted HR (95% CI) All* 1.00 1.41 (1.18–1.68) 1.55 (1.30–1.84) <0.001 0.977
SPRINT† 1.00 1.40 (1.07–1.82) 1.52 (1.18–1.95) 0.001
ACCORD† 1.00 1.42 (1.12–1.79) 1.57 (1.24–2.00) <0.001
Adjusted HR (95% CI)‡ All* 1.00 1.31 (1.09–1.56) 1.50 (1.24–1.81) <0.001 0.951
SPRINT† 1.00 1.27 (0.97–1.67) 1.50 (1.15–1.95) 0.003
ACCORD† 1.00 1.33 (1.05–1.69) 1.49 (1.15–1.92) 0.002
ACCORD primary outcome (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes)
No. events (%) SPRINT 67 (2.3) 94 (3.3) 105 (3.3) 0.020
ACCORD 97 (6.2) 135 (8.0) 120 (9.0) 0.004
Unadjusted HR (95% CI) All* 1.00 1.39 (1.14–1.70) 1.46 (1.19–1.78) <0.001 0.726
SPRINT† 1.00 1.52 (1.11–2.08) 1.49 (1.09–2.02) 0.015
ACCORD† 1.00 1.31 (1.01–1.70) 1.44 (1.10–1.88) 0.007
Adjusted HR (95% CI)‡ All* 1.00 1.27 (1.03–1.56) 1.35 (1.09–1.68) 0.008 0.832
SPRINT† 1.00 1.36 (0.99–1.88) 1.41 (1.03–1.93) 0.042
ACCORD† 1.00 1.20 (0.92–1.57) 1.31 (0.98–1.74) 0.065
Heart failure
No. events (%) SPRINT 21 (0.7) 36 (1.3) 55 (1.7) <0.001
ACCORD 36 (2.3) 54 (3.2) 49 (3.7) 0.028
Unadjusted HR (95% CI) All* 1.00 1.58 (1.13–2.20) 1.93 (1.40–2.67) <0.001 0.383
SPRINT† 1.00 1.86 (1.09–3.19) 2.51 (1.52–4.15) <0.001
ACCORD† 1.00 1.41 (0.92–2.14) 1.57 (1.02–2.42) 0.039
Adjusted HR (95% CI)‡ All* 1.00 1.45 (1.03–2.05) 1.97 (1.39–2.80) <0.001 0.209
SPRINT† 1.00 1.70 (0.98–2.95) 2.72 (1.61–4.58) <0.001
ACCORD† 1.00 1.31 (0.85–2.02) 1.51 (0.95–2.38) 0.080
Stroke
No. events (%) SPRINT 20 (0.7) 36 (1.3) 33 (1.0) 0.170
ACCORD 11 (0.7) 32 (1.9) 36 (2.7) <0.001
Unadjusted HR (95% CI) All* 1.00 2.21 (1.44–3.37) 2.30 (1.51–3.52) <0.001 0.092
SPRINT† 1.00 1.95 (1.13–3.36) 1.56 (0.90–2.72) 0.150
ACCORD† 1.00 2.71 (1.37–5.39) 3.78 (1.92–7.42) <0.001
Adjusted HR (95% CI)‡ All* 1.00 2.00 (1.29–3.08) 2.11 (1.34–3.30) 0.002 0.120
SPRINT† 1.00 1.72 (0.99–3.00) 1.44 (0.81–2.57) 0.277
ACCORD† 1.00 2.51 (1.26–5.01) 3.45 (1.71–6.95) <0.001
All-cause death
No. events (%) SPRINT 58 (2.0) 106 (3.7) 111 (3.5) <0.001
ACCORD 73 (4.7) 90 (5.4) 74 (5.6) 0.261
Unadjusted HR (95% CI) All* 1.00 1.49 (1.20–1.86) 1.45 (1.16–1.81) 0.002 0.035
SPRINT† 1.00 1.98 (1.44–2.73) 1.82 (1.33–2.51) <0.001
Continued
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(Figure S2). For the intensive group, SPRINT had 19.9%,
70.6%, and 9.5% and ACCORD had 20.0%, 73.8%, and 6.2% of
participants in the 3 classes of increasing visit-to-visit
variability. For the standard group, SPRINT had 16.5%,
72.3%, and 11.2% and ACCORD had 16.1%, 80.0%, and 3.9%
in these classes. Tests for differences between trials in
percentages for treatment groups combined and for each
treatment group separately had P<0.001.
For both trials, participants with higher visit-to-visit
variability were older, less often white, and more often
female. They also had worse kidney function, higher Fram-
ingham Risk Scores, urine albumin/creatinine ratios, and
baseline SBP and were more likely to be on antihypertensive
medication before randomization (Table S2). During the first
year, participants in both trials with higher visit-to-visit
variability used more medications, had more changes in the
number of medications, and were more likely to have low visit
adherence.
Incidence of each outcome was progressively higher for
participants in classes of higher visit-to-visit variability
(Table S3). The relationships of visit-to-visit variability classes
and outcomes were consistent between trials except for the
primary outcomes of SPRINT and ACCORD; the adjusted
hazard ratios of higher versus lower visit-to-visit variability in
ACCORD were higher than those in SPRINT for the 2
composite outcomes.
Finally, with 1 exception, the associations of intensive
versus standard treatment with the risks of all outcomes were
consistent across classes of visit-to-visit variability for both
trials (Figure S3).
In sensitivity analyses, similar results in the association of
achieved SBP and visit-to-visit variability with outcomes were
found for participants without missing SBP measurement
during the first year, except that there was no significant
difference between SPRINT and ACCORD in the relationship of
achieved SBP with stroke (Tables S4 and S5).
Discussion
Our principal findings are consistent with a hypothesis that a
smaller difference in the separation of achieved SBP between
the intensive and standard groups in ACCORD compared with
SPRINT may have contributed to the discordant results
between the trials. Although the average SBP levels achieved
in both trials were quite similar, there was much better
separation of the SBP between treatment groups in SPRINT
compared with ACCORD. Meanwhile, the relationship of
achieved SBP with outcomes was similar regardless of
treatment group in both trials, except for stroke and death.
Finally, although there was a difference in percentages of
participants in different visit-to-visit variability classes, it did
not appear to modify the risk relationship between the 2
treatment groups in both trials. There were some differences
in the participant characteristics of SPRINT and ACCORD; for
example, ACCORD included exclusively adults with diabetes
mellitus, whereas SPRINT excluded people with diabetes
mellitus. It is important to note that we tested whether SBP
had a similar modifying effect on outcomes for both SPRINT
and ACCORD and found that the relationship of SBP with
outcomes was largely similar despite some differences in
participant characteristics, suggesting comparability of SBP
response and cardiovascular risk in the 2 trials.
Some experts have commented that ACCORD lacked
power to detect meaningful differences in outcomes because
of the event rates being lower than expected.4 Our results
show that lower SBP reduced risks of cardiovascular
outcomes for both trials, but ACCORD had a higher percent-
age of standard-group participants with lower achieved SBP
compared with SPRINT, and that may have contributed to the
low event rate of the standard group. Furthermore, the large
overlap of achieved SBP between the treatment groups in
ACCORD may have diminished the contrast between the
groups and resulted in less power to detect a difference in
Table 2. Continued
Variable Participants
Tertile of Achieved SBP
P Value for Trend
P Value for Trial
Heterogeneity of HRs<122 mm Hg 122–134 mm Hg >134 mm Hg
ACCORD† 1.00 1.12 (0.83–1.53) 1.14 (0.82–1.57) 0.426
Adjusted HR (95% CI)‡ All* 1.00 1.36 (1.08–1.71) 1.38 (1.09–1.76) 0.011 0.098
SPRINT† 1.00 1.72 (1.24–2.39) 1.70 (1.22–2.37) 0.003
ACCORD† 1.00 1.08 (0.79–1.48) 1.11 (0.79–1.57) 0.530
ACCORD indicates Action to Control Cardiovascular Risk in Diabetes; CI, confidence interval; GFR, glomerular filtration rate; HR, hazard ratio; SBP, systolic blood pressure; SPRINT, Systolic
Blood Pressure Intervention Trial.
*Modeling of the pooled participants from SPRINT and ACCORD, with stratified baseline hazard functions by trial.
†Modeling separately of the participants from SPRINT or ACCORD.
‡Adjusted for age, race, sex, Framingham Risk Score, baseline SBP and diastolic blood pressure, use of antihypertensive medication before randomization, smoking status, aspirin use,
estimated GFR, history of clinical/subclinical cardiovascular disease, total cholesterol, high-density lipoprotein, triglycerides, glucose, urine albumin/creatinine ratio, body mass index,
statin use, number of antihypertensive medications used, visit adherence, and visit-to-visit variability class.
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outcomes. What is important is that assessing the average
SBP values in the trials was not sufficient to appreciate the
differences in the separation of the treatment groups.
Our study cannot determine the cause for the differences
in the distribution of achieved SBP between the trials. An
explanation is that the implementation of the intervention was
simply more effective in SPRINT. In addition, SPRINT was
singularly a blood pressure trial, whereas ACCORD had 3
components including the diabetes trial,10 a lipid trial, and a
blood pressure trial, which may have had some impact on SBP
responses. It is possible that the difference in the SBP
distribution was also related to underlying diabetes mellitus,
perhaps because controlling blood pressure in patients with
diabetes mellitus may be more difficult and slower.21,22
Our findings of the relationship between SBP and cardio-
vascular outcomes are consistent with the findings of 2 recent
comprehensive meta-analyses of blood pressure lower-
ing.23,24 Both meta-analyses included only randomized trials
of blood pressure lowering, and both concluded that lower
SBP—ideally to <130 mm Hg—was associated with a reduc-
tion in the risk of cardiovascular outcomes. One meta-analysis
concluded that the lowest risk of cardiovascular outcomes
and mortality was between 120 and 124 mm Hg,23 similar to
the 120 mm Hg target for the intensive arms of SPRINT and
ACCORD. Moreover, the randomized controlled trial with the
most similar intensive SBP target to SPRINT and ACCORD, the
SPS-3 (Secondary Prevention of Small Subcortical Strokes)
trial with a goal of <130 mm Hg in patients with recent
lacunar stroke compared with a standard goal of 130 to
149 mm Hg, found that treatment reduced the point esti-
mates of multiple cardiovascular outcomes, although the
results were not statistically significant.25
Our study has some limitations. First, this study is a
secondary analysis of existing data and was undertaken to
explore explanations for the differences in the trials. Although
we included all available covariates at baseline and during the
first year of the trials to minimize the effects of confounding,
the possibility of residual confounding and unmeasured
confounders cannot be eliminated. Second, no information is
currently available about the drugs used in SPRINT, and so we
could not explore differences in specific treatment strategies.
Third, there were differences in follow-up duration between
SPRINT and ACCORD. Although we found no evidence of the
relationship between SBP and outcomes changing over time
for both trials, we cannot rule out the possibility that SPRINT
might have shown a time-varying relationship if it had not been
stopped early. Fourth, we excluded participants with cardio-
vascular events during the first year in each trial, and that
reduced the number of events available for analysis, although
we still found a significant increase in risk with higher achieved
SBP. Furthermore, participants with more comorbidities and
higher nonadherence were preferentially excluded from the
standard group, which may have diminished the benefit for the
intensive group seen in the remaining participants. However,
the exclusion pattern in the trials was similar and should not
have had an important effect on the comparison of the trials to
each other. Last, the analysis was based on achieved SBP
instead of the intent-to-treat assignment groups, and this may
have introduced bias26; however, we adjusted for all available
participant characteristics and visit adherence, and no signif-
icant interaction with treatment was found. Our findings do not
likely fully explain the discordant results of SPRINT and
ACCORD. A recent meta-analysis shows that patients with
diabetes mellitus may have a significant but smaller relative
risk reduction in cardiovascular outcomes compared with
patients without diabetes mellitus for a given magnitude of
blood pressure lowering.24 A simulation analysis suggests that
differences in the number of drugs and diastolic blood
pressure between the trials could have contributed to the
differences.27
In conclusion, this study provides evidence that may help
explain the different results in SPRINT and ACCORD. The
principal discovery is that although the trials had similar
average SBP levels achieved in the 2 treatment groups at
1 year, they had different degrees of separation between the
intensive and standard treatment groups. There was also
other evidence of differences in SBP response, as indicated by
the visit-to-visit variability differences in the trials, although no
evidence of its contribution to different trial results was found.
The findings suggest that the greater overlap in SBP between
intensive and standard groups in ACCORD may have dimin-
ished the contrast between the groups and been the reason
for the smaller benefit estimate and the lack of statistical
significance. If true, then ACCORD should be viewed as more
consistent with the thesis that a more intensive SBP control
strategy is better—as shown in SPRINT.
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likelihood BIC* Proportion in class (%) 
   1 2 3 4 
1 class 485795 486185     
2 classes  483155 483622 61.6 38.4   
3 classes  482801 483313 18.1 73.3 8.6  
4 classes 482731 483288 3.4 47.4 46.4 2.8 
* BIC denotes the Bayesian Information Criteria. 
 










Table S2. Participant characteristics by visit-to-visit variability of systolic blood pressure (SBP).* 
Characteristic 
SPRINT ACCORD 



















899 (54.8) 3196 (49.6) 431 (46.0) <0.001 457 (55.4) 1688 (48.0) 142 (61.5) 0.248 
Baseline characteristics 
Age—yr 66.6±8.9 67.9±9.3 69.4±10.0 <0.001 61.9±7.1 62.8±6.5 64.0±6.9 <0.001 
White—no. (%) 952 (58.0) 3784 (58.7) 481 (51.4) 0.011 504 (61.1) 2068 (58.8) 112 (48.5) 0.005 
Female—no. (%) 428 (26.1) 2331 (36.1) 453 (48.4) <0.001 347 (42.1) 1701 (48.3) 131 (56.7) <0.001 
Body-mass index—
kg/m2 
30.1±5.4 29.9±5.8 29.4±6.2 0.006 31.6±5.6 32.3±5.4 32.3±5.7 0.006 
Framingham Risk 
Score—% 
23.9±11.4 24.6±12.4 26.6±13.9 <0.001 33.3±16.1 35.0±16.7 40.0±18.7 <0.001 
Estimated GFR—
ml/min/1.73 m2 
74.3±18.9 71.7±20.5 68.7±22.6 <0.001 91.9±23.4 90.8±22.9 85.1±24.3 0.001 
Cholesterol—mg/dl         
Total 189.4±41.8 190.2±40.4 191.7±44.1 0.185 187.5±40.7 192.3±42.2 198.4±41.6 <0.001 
High-density lipoprotein 51.2±13.4 53.0±14.5 55.1±15.7 <0.001 45.3±12.5 46.3±13.0 46.1±13.8 0.090 
Triglycerides—mg/dl 127.4±83.1 126.2±94.1 120.3±75.1 0.088 185.3±130.1 183.7±128.6 181.9±124.2 0.690 
Glucose—mg/dl 99.4±12.5 98.8±13.7 97.9±14.5 0.009 172.3±51.5 174.2±54.9 172.4±63.1 0.596 
Ratio of urinary albumin 
(mg) to creatinine (g) 
32.2±151.0 40.2±165.1 58.4±179.8 <0.001 52.4±174.8 84.3±246.0 170.6±411.8 <0.001 
Aspirin use—no. (%) 821 (50.0) 3317 (51.4) 160 (49.1) 0.995 420 (50.9) 1867 (53.1) 112 (48.5) 0.930 
Statin use—no. (%) 717 (43.7) 2810 (43.6) 394 (42.1) 0.574 552 (66.9) 2287 (65.0) 145 (62.8) 0.168 
Antihypertensive 
medication use—no. (%) 
1461 (89.0) 5849 (90.7) 861 (92.0) 0.008 711 (86.2) 3087 (87.7) 215 (93.1) 0.015 
Smoking—no. (%) 182 (11.1) 845 (13.1) 158 (16.9) <0.001 90 (10.9) 410 (11.7) 28 (12.1) 0.512 
Cardiovascular 
disease—no. (%) 
269 (16.4) 1272 (19.7) 239 (25.5) <0.001 288 (34.9) 1125 (32.0) 94 (40.7) 0.910 
Blood pressure—mmHg         
Systolic 136.3±10.6 139.5±15.1 146.5±22.2 <0.001 136.7±10.7 139.0±15.7 146.1±19.3 <0.001 
Diastolic 77.9 (10.3) 78.1 (11.7) 79.3 (15.0) 0.014 75.6 (8.9) 75.8 (10.1) 77.0 (11.1) 0.158 
Characteristics 0-1 year post-randomization 
No. antihypertensive 
medications 
2.0±1.0 2.2±1.0 2.5±1.0 <0.001 2.4±1.0 2.6±1.1 3.3±1.1 <0.001 
No. changes in no. 
antihypertensive 
medications 
0.7±0.9 1.2±1.1 1.8±1.3 <0.001 1.3±1.3 1.7±1.3 2.4±1.4 <0.001 
Visit adherence—no. 
(%)† 
89.9 82.9 81.0 <0.001 81.2 77.2 75.3 0.010 
* Plus-minus values are means ±SD. GFR denotes glomerular filtration rate. 
† Visit adherence was defined as not missing any visit during the first year post-randomization. SPRINT required 
the intensive and standard groups to have visits at 1, 3, 6, 9, and 12 months. ACCORD required the intensive group 
to have visits at 1, 2, 3, 4, 6, 8,10, and 12 months and the standard group at 1, 4, 8, and 12 months. 
  










Table S3. Post 1-year outcomes associated with visit-to-visit variability classes. 
Variable Participants 
Class of visit-to-visit variability 
P value 
for trend 
P value for trial 
heterogeneity of 
hazard ratio 
5.7 mmHg 10.8 mmHg 17.9 mmHg 
SPRINT primary outcome 
No. events (%) 
SPRINT 53 (3.2) 267 (4.1) 60 (6.4) <0.001 
 




All* 1.00 1.75 (1.41-2.18) 2.83 (2.12-3.77) <0.001 
0.032 SPRINT† 1.00 1.32 (0.99-1.78) 2.09 (1.44-3.02) <0.001 




All* 1.00 1.54 (1.24-1.92) 2.05 (1.53-2.76) <0.001 
0.019 SPRINT† 1.00 1.13 (0.84-1.51) 1.51 (1.03-2.19) 0.034 
ACCORD† 1.00 2.11 (1.51-2.94) 2.90 (1.83-4.59) <0.001 
ACCORD primary outcome 
No. events (%) 
SPRINT 37 (2.3) 185 (2.9) 44 (4.7) 0.001 
 




All* 1.00 1.79 (1.39-2.31) 2.76 (1.97-3.87) <0.001 
0.072 SPRINT† 1.00 1.31 (0.92-1.86) 2.18 (1.41-3.38) <0.001 




All* 1.00 1.61 (1.24-2.08) 2.04 (1.44-2.88) <0.001 
0.033 SPRINT† 1.00 1.12 (0.79-1.60) 1.59 (1.02-2.48) 0.042 
ACCORD† 1.00 2.19 (1.51-3.18) 2.45 (1.43-4.20) <0.001 
Heart failure 
No. events (%) 
SPRINT 12 (0.7) 76 (1.2) 24 (2.6) <0.001 
 




All* 1.00 1.79 (1.18-2.69) 4.28 (2.61-7.01) <0.001 
0.785 SPRINT† 1.00 1.67 (0.91-3.07) 3.68 (1.84-7.36) <0.001 




All* 1.00 1.40 (0.93-2.12) 2.50 (1.50-4.16) <0.001 
0.859 SPRINT† 1.00 1.29 (0.70-2.38) 2.19 (1.08-4.42) 0.019 
ACCORD† 1.00 1.50 (0.85-2.63) 2.89 (1.40-5.97) 0.005 
Stroke 
No. events (%) 
SPRINT 12 (0.7) 62 (1.0) 15 (1.6) 0.045 
 




All* 1.00 1.56 (0.97-2.50) 3.13 (1.73-5.66) <0.001 
0.391 SPRINT† 1.00 1.36 (0.73-2.51) 2.29 (1.07-4.89) 0.035 




All* 1.00 1.30 (0.81-2.10) 2.05 (1.11-3.79) 0.024 
0.413 SPRINT† 1.00 1.13 (0.60-2.10) 1.50 (0.69-3.27) 0.303 
ACCORD† 1.00 1.57 (0.75-3.29) 3.35 (1.29-8.69) 0.017 
All-cause death 
No. events (%) 
SPRINT 25 (1.5) 199 (3.1) 51 (5.4) <0.001 
 




All* 1.00 1.66 (1.26-2.18) 2.69 (1.89-3.84) <0.001 
0.116 SPRINT† 1.00 2.09 (1.38-3.17) 3.71 (2.30-5.99) <0.001 




All* 1.00 1.40 (1.06-1.84) 1.86 (1.29-2.68) <0.001 
0.159 SPRINT† 1.00 1.70 (1.12-2.59) 2.50 (1.53-4.07) <0.001 
ACCORD† 1.00 1.17 (0.81-1.69) 1.16 (0.61-2.18) 0.486 
 
CI denotes confidence interval. 
*Modeling of the pooled participants from SPRINT and ACCORD, with stratified baseline hazard functions by trial. 
†Modeling separately of the participants from SPRINT or ACCORD. 
‡Adjusted for age, race, sex, Framingham Risk Score, baseline systolic and diastolic blood pressure, use of 
antihypertensive medication before randomization, smoking status, aspirin use, estimated glomerular filtration rate, 
history of clinical/subclinical cardiovascular disease, total cholesterol, high-density lipoprotein, triglycerides, 
glucose, urine albumin/creatinine ratio, body-mass index, statin use, treatment assignment, number of 
antihypertensive medications used, visit adherence, and estimated achieved 1-year systolic blood pressure.   
 
  










Table S4. Post 1-year outcomes associated with estimated systolic blood pressure (SBP) achieved at 1 year, for 
participants without missing SBP measurements during the first year. 
Variable Participants 
Tertile of estimated achieved SBP 
P value 
for trend 
P value for trial 
heterogeneity of 
hazard ratios 
<122 mmHg 122-134 mmHg >134 mmHg 
SPRINT primary outcome 
No. events (%) 
SPRINT 81 (3.1) 108 (4.6) 122 (4.7) 0.005  




All* 1.00 1.45 (1.19-1.78) 1.61 (1.32-1.96) <0.001 
0.681 SPRINT† 1.00 1.52 (1.14-2.02) 1.54 (1.16-2.04) 0.003 




All* 1.00 1.32 (1.07-1.63) 1.53 (1.23-1.90) <0.001 
0.966 SPRINT† 1.00 1.34 (1.00-1.79) 1.50 (1.12-2.01) 0.007 
ACCORD† 1.00 1.31 (0.98-1.76) 1.55 (1.15-2.10) 0.004 
ACCORD primary outcome 
No. events (%) 
SPRINT 55 (2.1) 77 (3.3) 85 (3.3) 0.014  




All* 1.00 1.39 (1.10-1.75) 1.52 (1.21-1.92) <0.001 
0.552 SPRINT† 1.00 1.59 (1.12-2.24) 1.57 (1.12-2.21) 0.011 




All* 1.00 1.26 (0.99-1.60) 1.42 (1.10-1.82) 0.007 
0.725 SPRINT† 1.00 1.40 (0.99-1.99) 1.51 (1.06-2.15) 0.025 
ACCORD† 1.00 1.16 (0.84-1.59) 1.34 (0.96-1.86) 0.085 
Heart failure 
No. events (%) 
SPRINT 18 (0.7) 35 (1.5) 39 (1.5) 0.014 
 




All* 1.00 1.84 (1.24-2.73) 2.16 (1.47-3.18) <0.001 
0.572 SPRINT† 1.00 2.22 (1.26-3.92) 2.23 (1.28-3.90) 0.007 




All* 1.00 1.62 (1.08-2.43) 2.10 (1.39-3.17) <0.001 
0.812 SPRINT† 1.00 1.86 (1.04-3.31) 2.29 (1.28-4.08) 0.006 
ACCORD† 1.00 1.43 (0.83-2.48) 1.92 (1.10-3.36) 0.020 
Stroke 
No. events (%) 
SPRINT 18 (0.7) 29 (1.2) 25 (1.0) 0.324 
 




All* 1.00 1.98 (1.24-3.17) 1.97 (1.23-3.15) 0.007 
0.208 SPRINT† 1.00 1.82 (1.01-3.28) 1.41 (0.77-2.59) 0.294 




All* 1.00 1.82 (1.13-2.96) 1.80 (1.09-2.98) 0.033 
0.334 SPRINT† 1.00 1.61 (0.88-2.93) 1.34 (0.71-2.52) 0.414 
ACCORD† 1.00 2.34 (1.04-5.24) 2.79 (1.24-6.30) 0.017 
All-cause death 
No. events (%) 
SPRINT 43 (1.7) 84 (3.6) 80 (3.1) 0.002 
 




All* 1.00 1.58 (1.21-2.07) 1.49 (1.13-1.96) 0.006 
0.017 SPRINT† 1.00 2.22 (1.54-3.20) 1.91 (1.32-2.77) 0.001 




All* 1.00 1.38 (1.05-1.82) 1.33 (1.00-1.78) 0.078 
0.028 SPRINT† 1.00 1.88 (1.29-2.73) 1.75 (1.19-2.57) 0.009 
ACCORD† 1.00 0.93 (0.62-1.39) 0.92 (0.60-1.42) 0.727 
 
CI denotes confidence interval. 
*Modeling of the pooled participants from SPRINT and ACCORD, with stratified baseline hazard functions by trial. 
†Modeling separately of the participants from SPRINT or ACCORD. 
‡Adjusted for age, race, sex, Framingham risk score, baseline systolic and diastolic blood pressure, use of 
antihypertensive medication before randomization, smoking status, aspirin use, estimated glomerular filtration rate, 
history of clinical/subclinical cardiovascular disease, total cholesterol, high-density lipoprotein, triglycerides, 
glucose, urine albumin/creatinine ratio, body-mass index, statin use, number of antihypertensive medications used 
and visit-to-visit variability class.   
 
  










Table S5. Post 1-year outcomes associated with visit-to-visit variability, for participants without missing SBP 
measurements during the first year. 
Variable Participants 
Class of visit-to-visit variability 
P value 
for trend 
P value for trial 
heterogeneity of 
hazard ratios 
5.3 mmHg 10.3mmHg 17.0 mmHg 
SPRINT primary outcome 
No. events (%) 
SPRINT 40 (3.3) 208 (3.8) 63 (6.6) <0.001  




All* 1.00 1.75 (1.33-2.30) 3.00 (2.18-4.12) <0.001 
0.006 SPRINT† 1.00 1.17 (0.83-1.64) 2.03 (1.37-3.02) <0.001 




All* 1.00 1.53 (1.16-2.01) 2.13 (1.53-2.96) <0.001 
0.002 SPRINT† 1.00 0.97 (0.69-1.37) 1.38 (0.92-2.07) 0.072 
ACCORD† 1.00 2.76 (1.71-4.46) 3.86 (2.22-6.72) <0.001 
ACCORD primary outcome 
No. events (%) 
SPRINT 26 (2.2) 147 (2.7) 44 (4.6) 0.001  




All* 1.00 1.84 (1.33-2.53) 2.84 (1.95-4.14) <0.001 
0.064 SPRINT† 1.00 1.27 (0.84-1.93) 2.17 (1.34-3.53) 0.001 




All* 1.00 1.64 (1.19-2.26) 2.06 (1.39-3.04) <0.001 
0.032 SPRINT† 1.00 1.08 (0.71-1.64) 1.52 (0.92-2.48) 0.068 
ACCORD† 1.00 2.55 (1.53-4.24) 2.86 (1.55-5.28) <0.001 
Heart failure 
No. events (%) 
SPRINT 10 (0.8) 58 (1.1) 24 (2.5) <0.001 
 




All* 1.00 2.03 (1.17-3.51) 5.06 (2.78-9.23) <0.001 
0.178 SPRINT† 1.00 1.31 (0.67-2.56) 3.08 (1.48-6.45) <0.001 




All* 1.00 1.40 (0.93-2.12) 2.50 (1.50-4.16) <0.001 
0.153 SPRINT† 1.00 1.01 (0.51-1.98) 1.73 (0.82-3.66) 0.070 
ACCORD† 1.00 3.08 (1.13-8.45) 6.19 (2.09-18.31) <0.001 
Stroke 
No. events (%) 
SPRINT 10 (0.8) 47 (0.9) 15 (1.6) 0.103 
 




All* 1.00 1.18 (0.69-2.01) 2.57 (1.38-4.77) 0.002 
0.484 SPRINT† 1.00 1.06 (0.53-2.09) 1.92 (0.86-4.28) 0.095 




All* 1.00 1.03 (0.60-1.76) 1.78 (0.93-3.39) 0.057 
0.399 SPRINT† 1.00 0.90 (0.45-1.79) 1.28 (0.56-2.90) 0.493 
ACCORD† 1.00 1.26 (0.53-2.97) 2.92 (1.07-7.97) 0.025 
All-cause death 
No. events (%) 
SPRINT 16 (1.3) 148 (2.7) 43 (4.5) <0.001 
 




All* 1.00 1.78 (1.23-2.57) 2.78 (1.81-4.27) <0.001 
0.517 SPRINT† 1.00 2.08 (1.24-3.49) 3.42 (1.93-6.08) <0.001 




All†* 1.00 1.56 (1.08-2.25) 2.01 (1.29-3.13) 0.002 
0.633 SPRINT† 1.00 1.78 (1.06-2.99) 2.40 (1.34-4.31) 0.003 
ACCORD† 1.00 1.33 (0.79-2.25) 1.55 (0.77-3.12) 0.205 
 
CI denotes confidence interval. 
*Modeling of the pooled participants from SPRINT and ACCORD, with stratified baseline hazard functions by trial. 
†Modeling separately of the participants from SPRINT or ACCORD. 
‡Adjusted for age, race, sex, Framingham Risk Score, baseline systolic and diastolic blood pressure, use of 
antihypertensive medication before randomization, smoking status, aspirin use, estimated glomerular filtration rate, 
history of clinical/subclinical cardiovascular disease, total cholesterol, high-density lipoprotein, triglycerides, 
glucose, urine albumin/creatinine ratio, body-mass index, statin use, treatment assignment, number of 
antihypertensive medications used, and estimated achieved 1-year SBP.   
 










Figure S1. Hazard ratios of post 1-year outcomes associated with estimated SBP achieved at 1 year for 
SPRINT and ACCORD, using restricted cubic splines. 
 
  










Figure S2. Distribution of visit-to-visit variability classes for participants from the intensive and standard 





Bars represent percentages of participants assigned to 3 classes of visit-to-visit variability. 
 
  










Figure S3. Hazard ratios of post 1-year outcomes associated with intensive versus standard treatment for 




* HR denotes the hazard ratio and CI the confidence interval.  
Hazard ratios were adjusted for age, race, sex, Framingham Risk Score, baseline systolic and diastolic blood 
pressure, use of antihypertensive medication before randomization, smoking status, aspirin use, estimated 
glomerular filtration rate, history of clinical/subclinical cardiovascular disease, total cholesterol, high-density 
lipoprotein, triglycerides, glucose, urine albumin/creatinine ratio, body-mass index, statin use, number of 
antihypertensive medications used, visit adherence, and estimated achieved 1-year SBP.  All interactions were not 
significant for visit-to-visit variability class and each outcome except for heart failure in SPRINT (class 2 vs class 1 
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